What a Demo Day at GIMS Taught Us About Clinical AI in India

On 18 May 2026, we carried Mobilab into the Center for Medical Innovation at GIMS, Greater Noida — CMI-GIMS — for the AI Roundtable & MedTech Hospital Demo Day 2026. Running alongside it were two more sessions built to keep everyone honest: "AI for Doctors — From Doctors," and the 2nd Edition MedTech Regulatory Clinic. If you wanted a soft launchpad for a healthtech pitch, this was the opposite of that.

The room was a cross-section of everyone who gets a vote on whether a medical technology lives or dies: clinicians, MedTech founders, AI researchers, investors, academics, policymakers, and regulatory specialists — with faces from AIIMS New Delhi, Sharda University, Bennett University, the Export Promotion Council for Medical Devices, the science-and-technology desk of the Vietnam Embassy, and the startup-incubation community, among others.

We came to pitch a product. We left with something we value far more. Here's how the day unfolded — and what it told us about where Clinical AI in India is actually headed.

Phase 1: The doctors take the floor

The day didn't open with slides. It opened with a roundtable.

No one was selling anything. Clinicians, regulators, and academics simply sat down to argue the hard questions out loud — the ones every honest person in this field is quietly carrying. Who validates these algorithms? Who is accountable when an AI informs a care decision? Can any of this actually survive in a Tier 2 town, or is it all quietly built for metro hospitals?

The chief guest, Dr. Surendra Singh—former Drug Controller General of India (DCGI) and now Vice-Chancellor of Mahayogi Guru Gorakhnath University—set the tone, pressing on the need for ethical, validated AI and proper institutional frameworks before these tools touch patients. Prof. Rana Pratap Singh, Vice-Chancellor of Gautam Buddha University, kept returning to a single non-negotiable: patient safety has to come first, every time, as these technologies move from demo to bedside.

Sitting in that room, one thing became clear. The conversation around clinical AI in India has grown up. The market has stopped asking, "Is this AI impressive?" It is now asking, "Is this AI trustworthy?"

For a company like ours, that is the best possible question to be asked—because trust is the thing we chose to build first.

Phase 2: We step up to pitch

Then the room changed gear.

Then the room changed gear.

Phase 2 was the demo and pitch session—Mobilab, alongside other innovators, presenting to a panel of doctors and investors who had just spent the morning stress-testing the entire premise of clinical AI. No warm-up crowd. The toughest possible audience, freshly armed with the toughest possible questions.

And the cohort itself was a reminder of how far homegrown MedTech has come. Around us were teams building assistive robotics to restore movement for people living with paralysis and quietly clever bedside devices solving problems most hospitals had simply learned to live with. Set those alongside our own portable diagnostics, and a pattern jumps out: Indian health tech is moving away from giant machines locked inside metro hospitals toward affordable, deployable, human-centered devices that meet the patient where they are. Pitching beside builders like that felt less like competition and more like a shared mission. 

Then it was our turn. We opened the case and set up the device—and the very first reaction had nothing to do with technology.

A doctor leaned in, looked at the open suitcase on the table, and asked, "This is the whole lab?"

Yes. That's the whole point.

As India's first AI-powered portable diagnostic platform, Mobilab runs 25+ blood tests from a single venous blood sample, with results in about 30 minutes — right there, at the point of care. We watched the panel do the mental math in real time. What would this mean for my clinic? For my outreach camp? For the patient who travels two hours, gives a sample, and never comes back to collect the report?

That pause — that quiet calculation — is the moment a pitch stops being a pitch and becomes a conversation.

The questions we were ready for

The doctors went straight for the jugular. How accurate? Validated by whom? What's the regulatory status? This is exactly where our story does the heavy lifting, because we never have to ask anyone to simply take our word.

When ICMR and AIIMS Delhi come together to assess a platform, it usually means something. When they come together to actively back it, it means more. That's what happened with Mobilab—not a one-off study tucked into a footnote, but two of India's most respected medical institutions putting their weight behind homegrown health tech.

The credentials sit underneath all of it: CDSCO-licensed, ISO 13485:2016 certified, and engineered at IIT Guwahati. Say those names in sequence to a skeptical clinician and you can watch the arms uncross. 

The investors were pulling a different thread—scale. India has tens of thousands of clinics across Tier 2 and Tier 3 towns with no pathology lab anywhere nearby. The real opportunity was never a slightly better lab in the metros. It's putting a lab where there has never been one. That is a story that responsible clinical AI in India is uniquely positioned to tell—and to deliver on.

The other innovators made the day genuinely enjoyable. There's a quiet camaraderie among people building trustworthy health tech the hard way—through validation rather than hype. Pitching beside them felt less like a competition and more like a shared mission.

A point the Regulatory Clinic drove home

The MedTech Regulatory Clinic running in parallel made something explicit that we believe in our bones: building safe, ethical, clinically validated technology is a shared responsibility. Doctors, regulators, academics, and startups each hold a piece of it. No single one of them can carry it alone—and days like this are where the pieces actually come together in the same room.

It's easy to talk about "the ecosystem" as an abstraction. It's another thing to sit at the table and feel it working.

What changed by the end of the day

We arrived to present a product across two phases. We left with something better.

A roomful of serious people—the very people who had spent the morning poking holes in the entire category—were now associating Mobilab with the right things: clinical rigor, real validation, and a genuine answer to India's access problem. The skepticism didn't disappear; it got satisfied. That's a much stronger place to end up.

Our thanks to CMI-GIMS for creating a space where innovation gets pressure-tested by the people who matter most — the ones who will actually use it on patients.

We walked in to pitch. We walked out with new partners, new conversations, and a renewed conviction that the future of healthcare here will be built on trust, not noise.

That's the future we're building toward — Smarter Health for All.